Baymatob has successfully completed a competitive selection process to be awarded a grant in the inaugural cohort of the CUREator+ accelerator program. This program, funded by the Australian Government’s Medical Research Future Fund (MRFF), is delivered by partnership of ANDHealth and Brandon BioCatalyst. Baymatob has been awarded a share of this $18.5M funding along with seven other top class Australian health innovation companies.
Brandon BioCatalyst CEO, Dr Chris Nave, said “The high quality of CUREator+ round one companies is exciting and evidence of Australia's scientific potential.”
ANDHealth CEO & MD, Bronwyn Le Grice, said “In the current market, substantive equity-free funding such as provided under CUREator+ and access to global industry leaders with proven track records, can make a material difference to the speed and success of commercialising these exciting new technologies.”
Baymatob CEO, Tara Croft, said “Receiving this support from the MRRF, ANDHealth, and Brandon BioCatalyst allows Baymatob to achieve a number of valuable milestones in our clinical and regulatory pathways. These are crucial to helping us attain our goal to revolutionise maternal healthcare and improve outcomes for clinicians, mothers, and babies.”
For more information see: https://www.andhealth.com.au/news/cureator-deploys-18-5-million-in-its-first-funding-round